Tacrolimus ointment in the treatment of hormone-dependent dermatitis: A protocol of systematic review.

Abstract

BACKGROUND:

Long-term use of corticosteroid ointment for external using or skin management products and cosmetics containing corticosteroid will produce a hormone-dependent effect on facial skin and destroy the barrier function of the skin. It is easy to cause repeated attacks of facial skin inflammation after drug withdrawal because corticosteroid hormones can cause the expression of inflammatory factors in the body, which has a serious impact on patients. The general treatment method is to stop using hormone drugs for psychotherapy and inform patients of the basic knowledge of hormone-dependent dermatitis and daily facial care, but the effect is not good. At present, non-steroidal ointment tacrolimus (a calcineurin inhibitor) is widely used in the treatment of hormone-dependent dermatitis. Tacrolimus ointment is effective for corticosteroid-dependent dermatitis, but adverse events can also occur.

METHODS:

We plan to searched all randomized controlled trials (RCTs) fortacrolimus ointment therapy of hormone-dependent dermatitis in: MEDLINE, PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Springer and Web of Science, China Biomedical Literature Database (CBM), China Science Journal Database (VIP database) and Wanfang Database, China National Knowledge Infrastructure (CNKI), without the limitation of publication status and language until September 1, 2020. The systematic review will also search will also search for identify publications, meeting minutes, and grey literature (including unpublished meeting articles).

DISCUSSION:

The systematic review mainly to access the safety and efficacy of tacrolimus ointment for hormone-dependent dermatitis (facial corticosteroid addiction dermatitis and facial steroid dermatitis). The results of our research will facilitate evidence-based management of patients with facial corticosteroid-dependent dermatitis and provide clinical advice on their treatment options.

REGISTRATION:

PROSPERO CRD42020171813.

• Authors: Mao Li, Wen Tan, Jingjing Du, Qiuyue Wang, Linyue Wang, Min Lei, Ping-Sheng Hao
• Journal: Medicine (Medicine (Baltimore)) Vol. 99 Issue 37 Pg. e22159 (Sep 11 2020) ISSN: 1536-5964 [Electronic] United States
• PMID: 32925777 (Publication Type: Journal Article, Systematic Review)

Chemical References

• Adrenal Cortex Hormones
• Calcineurin Inhibitors
• Ointments
• Tacrolimus

Topics

• Administration, Cutaneous
• Adrenal Cortex Hormones (administration & dosage, adverse effects)
• Calcineurin Inhibitors (administration & dosage, therapeutic use)
• Drug Eruptions (drug therapy, etiology)
• Humans
• Ointments
• Randomized Controlled Trials as Topic
• Research Design
• Tacrolimus (administration & dosage, therapeutic use)